Advertisement

Does FAD-dependent polyamine oxidase contribute to the metabolism of milacemide?

  • M. Strolin Benedetti
  • G. Cocchiara
  • M. Colombo
  • P. Dostert
Conference paper
Part of the Journal of Neural Transmission book series (NEURAL SUPPL, volume 32)

Summary

Milacemide, a secondary amine derivative, was previously demonstrated to be a substrate of MAO-B and to be insensitive to the action of copper-dependent amine oxidases. In the present study, it was investigated whether the FAD-dependent secondary amine metabolizing enzyme polyamine oxidase (PAO), could participate in the metabolism of milacemide. For this purpose, the urinary metabolic pattern of oral 14C-milacemide was determined in rats with and without pretreatment with the irreversible PAO inhibitor MDL 72527 and, for comparison, after inhibition of MAO-B by 1-deprenyl.

While 1-deprenyl was shown to significantly decrease the urinary excretion of glycinamide and of an unknown metabolite (UK1, pretreatment with MDL 72527 did not modify the elimination of milacemide as glycinamide but produced a decrease in UK1 equal to that induced by 1-deprenyl. The percent of the dose of milacemide eliminated as unchanged drug was slightly but significantly increased after PAO inhibition, though considerably less than after 1-deprenyl. These data suggest that milacemide might be a substrate of PAO. If confirmed, this result would constitute the first example of the involvement of the FAD-dependent PAO in drug metabolism.

Keywords

Monoamine Oxidase Secondary Amine Amine Oxidase Polyamine Oxidase Unknown Metabolite 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Barrand MA, Callingham BA (1982) Monoamine oxidase activities in brown adipose tissue of the rat: some properties and subcellular distribution. Biochem Pharmacol 31:2177–2184.PubMedCrossRefGoogle Scholar
  2. Bolkenius FN, Bey P, Seiler N (1985) Specific inhibition of polyamine oxidase in vivo is a method for the elucidation of its physiological role. Biochim Biophys Acta 838:69–76.PubMedCrossRefGoogle Scholar
  3. Guffroy C, Fowler CJ, Strolin Benedetti M (1983) The deamination of n-pentylamine by monoamine oxidase and a semicarbazide-sensitive amine oxidase of rat heart. J Pharm Pharmacol 35:416–420.PubMedCrossRefGoogle Scholar
  4. Hölltä E (1977) Oxidation of spermidine and spermine in rat liver: purification and properties of polyamine oxidase. Biochemistry 16:91–100.CrossRefGoogle Scholar
  5. Janssens de Varebeke P, Cavalier R, David-Remacle M, Youdim MBH (1988) Formation of the neurotransmitter glycine from the anticonvulsant milacemide is mediated by brain monoamine oxidase. J Neurochem 50:1011–1016.PubMedCrossRefGoogle Scholar
  6. Janssens de Varebeke P, Pauwels G, Buyse C, David-Remacle M, De Mey J, Roba J, Youdim MBH (1989) The novel neuropsychotropic agent milacemide is a specific enzyme-activated inhibitor of brain monamine oxidase B. J Neurochem 53:1109–1116.PubMedCrossRefGoogle Scholar
  7. Seiler N (1987) Inhibition of enzymes oxidizing polyamines. In: McCann PP, Pegg AE, Sjoerdsma A (eds) Inhibition of polyamine metabolism. Academic Press, Orlando, pp 49–77.Google Scholar
  8. Seiler N, Bolkenius FN, Knödgen B, Mamont P (1980) Polyamine oxidase in rat tissues. Biochim Biophys Acta 615:480–488.PubMedGoogle Scholar
  9. Strolin Benedetti M (1989) Oxidative drug metabolism not cytochrom P-450 dependent. Actual Chim Thér 16:337–356.Google Scholar
  10. Strolin Benedetti M, Sontag N, Boucher T, Kan JP (1981) Aliphatic amines as MAO substrates in the rat: the effect of selective inhibitors on the deamination of n-pentylamine. In: Usdin E, Weiner N, Youdim MBH (eds) Function and regulation of monoamine enzymes. Macmillan, London, pp 527–538.Google Scholar
  11. Strolin Benedetti M, Dostert P, Guffroy C, Tipton KF (1983) Partial or total protection from long-acting monoamine oxidase inhibitors by new short-acting MAOIs of type A MD 780515 and type B MD 780236. Mod Probl Pharmacopsychiatry 19:82–104.Google Scholar
  12. Strolin Benedetti M, Marrari P, Moro E, Dostert P, Roncucci R (1988) Do amineoxidases contribute to the metabolism of milacemide?. Pharmacol Res Commun 20 [Suppl] 4:135–136.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1990

Authors and Affiliations

  • M. Strolin Benedetti
    • 1
  • G. Cocchiara
    • 1
  • M. Colombo
    • 1
  • P. Dostert
    • 1
  1. 1.Research and Development — Erbamont GroupFarmitalia Carlo Erba, R&DMilanItaly

Personalised recommendations